Interferon-γ, a valuable surrogate marker of Plasmodium falciparum pre-erythrocytic stages protective immunity

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Perlaza, Blanca Liliana ^a   Sauzet, Jean Pierre ^a   Brahimi, Karima ^a   Benmohamed, Lbachir ^b   Druilhe, Pierre ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; SPOROZOITE VACCINE; BIOLOGICAL MARKER; MALARIA VACCINE;

AOTUS; ARTICLE; CHIMPANZEE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MALARIA FALCIPARUM; NONHUMAN; PLASMODIUM FALCIPARUM; SPOROZOITE; ANIMAL; DISEASE MODEL; ERYTHROCYTE; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MALARIA; MOUSE; PARASITOLOGY; PLASMODIUM; PRIMATE;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; ERYTHROCYTES; HUMANS; INTERFERON-GAMMA; MALARIA; MALARIA VACCINES; MICE; PLASMODIUM; PLASMODIUM FALCIPARUM; PRIMATES; SPOROZOITES;

EID: 79551684627     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-27     Document Type: Article

References (80)

1. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. DF Clyde VC McCarthy RM Miller RB Hornick, Am J Med Sci 1973 266 398 403 10.1097/00000441-197312000-00001 4590095
2. Immunization of man against sporozite-induced falciparum malaria. DF Clyde H Most VC McCarthy JP Vanderberg, Am J Med Sci 1973 266 169 177 10.1097/00000441-197309000-00002 4583408
3. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. RS Nussenzweig J Vanderberg H Most C Orton, Nature 1967 216 160 162 10.1038/216160a0 6057225
4. Pre-erythrocytic malaria vaccines: towards greater efficacy. AV Hill, Nat Rev Immunol 2006 6 21 32 10.1038/nri1746 16493425 (Pubitemid 43279750)
5. Immune effector mechanisms in malaria. K Marsh S Kinyanjui, Parasite Immunol 2006 28 51 60 10.1111/j.1365-3024.2006.00808.x 16438676
6. Pre-erythrocytic stage malaria vaccines: time for a change in path. P Druilhe JW Barnwell, Curr Opin Microbiol 2007 10 371 378 10.1016/j.mib.2007.07. 009 17709281 (Pubitemid 47411627)
7. The complexity of protective immunity against liver-stage malaria. DL Doolan SL Hoffman, J Immunol 2000 165 1453 1462 10903750 (Pubitemid 30604578)
8. How reliable are models for malaria vaccine development? Lessons from irradiated sporozoite immunizations. S Chatterjee JL Perignon E Van Marck P Druilhe, J Postgrad Med 2006 52 321 324 17102561 (Pubitemid 44862783)
9. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites. J Vanderberg R Nussenzweig H Most, Mil Med 1969 134 1183 1190 4987037
10. Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine. R Schwenk LV Asher I Chalom D Lanar P Sun K White D Keil KE Kester J Stoute DG Heppner U Krzych, Parasite Immunol 2003 25 17 25 10.1046/j.1365-3024. 2003.00495.x 12753434 (Pubitemid 38019095)
11. Hepatic phase of malaria is the target of cellular mechanisms induced by the previous and the subsequent stages. A crucial role for liver nonparenchymal cells. D Mazier L Renia A Nussler S Pied M Marussig J Goma D Grillot F Miltgen JC Drapier G Corradin G Del Giudice GE Grau, Immunol Lett 1990 25 65 70 10.1016/0165-2478(90)90093-6 1980910 (Pubitemid 20260847)
12. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. MR Hollingdale EH Nardin S Tharavanij AL Schwartz RS Nussenzweig, J Immunol 1984 132 909 913 6317752 (Pubitemid 14189116)
13. Evaluation of an in vitro assay aimed at measuring protective antibodies against sporozoites. S Mellouk N Berbiguier P Druilhe M Sedegah B Galey L Yuan M Leef Y Charoenvit C Paul S Hoffman RL Beaudoin, Bull World Health Organ 1990 68 52 59 2094592
14. Generation and characterization of malaria-specific human CD8(+) lymphocyte clones: effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentationby liver cells. A Bonelo D Valmori F Triponez JM Tiercy G Mentha J Oberholzer P Champagne JF Romero F Esposito I Nebie C Barbey P Romero S Herrera G Corradin JA Lopez, Eur J Immunol 2000 30 3079 3088 10.1002/1521-4141(200011)30:11<3079::AID-IMMU3079>3.0.CO;2-7 11093122
15. Plasmodium berghei-infected primary hepatocytes process and present the circumsporozoite protein to specific CD8+ T cells in vitro. SE Bongfen R Torgler JF Romero L Renia G Corradin, J Immunol 2007 178 7054 7063 17513754 (Pubitemid 46847431)
16. Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages. L Renia D Grillot M Marussig G Corradin F Miltgen PH Lambert D Mazier G Del Giudice, J Immunol 1993 150 1471 1478 7679428 (Pubitemid 23127437)
17. CD4+ cytolytic T cell clone confers protection against murine malaria. M Tsuji P Romero R Nussenzweig F Zavala, J Exp Med 1990 172 1353 1357 10.1084/jem.172.5.1353 2146361 (Pubitemid 20366210)
18. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. WR Weiss S Mellouk RA Houghten M Sedegah S Kumar MF Good JA Berzofsky LH Miller SL Hoffman, J Exp Med 1990 171 763 773 10.1084/jem.171.3.763 1689762 (Pubitemid 20088980)
19. The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoite-induced protection against malaria. M Rodrigues RS Nussenzweig F Zavala, Immunology 1993 80 1 5 7902331 (Pubitemid 23284179)
20. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. L Schofield A Ferreira R Altszuler V Nussenzweig RS Nussenzweig, J Immunol 1987 139 2020 2025 2957445 (Pubitemid 17141640)
21. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. WR Weiss M Sedegah RL Beaudoin LH Miller MF Good, Proc Natl Acad Sci USA 1988 85 573 576 10.1073/pnas.85.2.573 2963334 (Pubitemid 18059317)
22. The role of CD4+ T cells in immunity to malaria sporozoites. WR Weiss M Sedegah JA Berzofsky SL Hoffman, J Immunol 1993 151 2690 2698 8103069 (Pubitemid 23264520)
23. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. S Khusmith Y Charoenvit S Kumar M Sedegah RL Beaudoin SL Hoffman, Science 1991 252 715 718 10.1126/science.1827210 1827210 (Pubitemid 21917001)
24. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. MM Rodrigues AS Cordey G Arreaza G Corradin P Romero JL Maryanski RS Nussenzweig F Zavala, Int Immunol 1991 3 579 585 10.1093/intimm/3.6.579 1716146
25. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. P Romero JL Maryanski G Corradin RS Nussenzweig V Nussenzweig F Zavala, Nature 1989 341 323 326 10.1038/341323a0 2477703 (Pubitemid 20102099)
26. Plasmodium yoelii: peptide immunization induces protective CD4+ T cells against a previously unrecognized cryptic epitope of the circumsporozoite protein. Y Takita-Sonoda M Tsuji K Kamboj RS Nussenzweig P Clavijo F Zavala, Exp Parasitol 1996 84 223 230 10.1006/expr.1996.0108 8932772 (Pubitemid 26399788)
27. A retrospective evaluation of the role of T cells in the development of malaria vaccine. M Tsuji, Exp Parasitol 2009 126 421 425 10.1016/j.exppara.2009. 11.009 19944099
28. Gamma delta T cells contribute to immunity against the liver stages of malaria in alpha beta T-cell-deficient mice. M Tsuji P Mombaerts L Lefrancois RS Nussenzweig F Zavala S Tonegawa, Proc Natl Acad Sci USA 1994 91 345 349 10.1073/pnas.91.1.345 8278391
29. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. DL Doolan SL Hoffman, J Immunol 1999 163 884 892 10395683 (Pubitemid 29328098)
30. NK cell responses to Plasmodium infection and control of intrahepatic parasite development. J Roland V Soulard C Sellier AM Drapier JP Di Santo PA Cazenave S Pied, J Immunol 2006 177 1229 1239 16818782 (Pubitemid 44036628)
31. Liver CD4-CD8- NK1.1+ TCR alpha beta intermediate cells increase during experimental malaria infection and are able to exhibit inhibitory activity against the parasite liver stage in vitro. S Pied J Roland A Louise D Voegtle V Soulard D Mazier PA Cazenave, J Immunol 2000 164 1463 1469 10640763 (Pubitemid 30067262)
32. Starring stellate cells in liver immunology. F Winau C Quack A Darmoise SH Kaufmann, Curr Opin Immunol 2008 20 68 74 10.1016/j.coi.2007.10.006 18068343
33. Interleukin 12 induction of interferon gamma-dependent protection against malaria. M Sedegah F Finkelman SL Hoffman, Proc Natl Acad Sci USA 1994 91 10700 10702 10.1073/pnas.91.22.10700 7938013 (Pubitemid 24329066)
34. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. A Ferreira L Schofield V Enea H Schellekens P van der Meide W Collins R Nussenzweig V Nussenzweig, Science 1986 232 881 884 10.1126/science.3085218 3085218 (Pubitemid 16117400)
35. Inhibitory activity of interferons and interleukin 1 on the development of Plasmodium falciparum in human hepatocyte cultures. S Mellouk RK Maheshwari A Rhodes-Feuillette RL Beaudoin N Berbiguier H Matile F Miltgen I Landau S Pied JP Chigot RM Friedman D Mazier, J Immunol 1987 139 4192 4195 2447163 (Pubitemid 18013718)
36. Development of antimalaria immunity in mice lacking IFN-gamma receptor. M Tsuji Y Miyahira RS Nussenzweig M Aguet M Reichel F Zavala, J Immunol 1995 154 5338 5344 7537305
37. The role of cell-mediated immune responses in resistance to malaria, with special reference to oxidant stress. AC Allison EM Eugui, Annu Rev Immunol 1983 1 361 392 10.1146/annurev.iy.01.040183.002045 6100538
38. Nitric oxide-mediated antiplasmodial activity in human and murine hepatocytes induced by gamma interferon and the parasite itself: enhancement by exogenous tetrahydrobiopterin. S Mellouk SL Hoffman ZZ Liu P de la Vega TR Billiar AK Nussler, Infect Immun 1994 62 4043 4046 8063424 (Pubitemid 24264354)
39. In vivo induction of the nitric oxide pathway in hepatocytes after injection with irradiated malaria sporozoites, malaria blood parasites or adjuvants. AK Nussler L Renia V Pasquetto F Miltgen H Matile D Mazier, Eur J Immunol 1993 23 882 887 10.1002/eji.1830230417 8458376 (Pubitemid 23101073)
40. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells. MC Seguin FW Klotz I Schneider JP Weir M Goodbary M Slayter JJ Raney JU Aniagolu SJ Green, J Exp Med 1994 180 353 358 10.1084/jem.180.1.353 7516412 (Pubitemid 24181084)
41. The role of TNF in parasitic diseases: still more questions than answers. H Korner B McMorran D Schluter P Fromm, Int J Parasitol 2010 40 879 888 10.1016/j.ijpara.2010.03.011 20399786
42. L-arginine-dependent destruction of intrahepatic malaria parasites in response to tumor necrosis factor and/or interleukin 6 stimulation. A Nussler JC Drapier L Renia S Pied F Miltgen M Gentilini D Mazier, Eur J Immunol 1991 21 227 230 10.1002/eji.1830210134 1991487
43. Inhibitory activity of IL-6 on malaria hepatic stages. S Pied L Renia A Nussler F Miltgen D Mazier, Parasite Immunol 1991 13 211 217 10.1111/j.1365-3024.1991.tb00276.x 2052407
44. C-reactive protein protects against preerythrocytic stages of malaria. S Pied A Nussler M Pontent F Miltgen H Matile PH Lambert D Mazier, Infect Immun 1989 57 278 282 2642467 (Pubitemid 19024651)
45. Non specific resistance against malaria pre-erythrocytic stages: involvement of acute phase proteins. S Pied MD Tabone G Chatellier M Marussig C Jardel F Nosten D Mazier, Parasite 1995 2 263 268 8520801
46. The importance of models of infection in the study of disease resistance. P Druilhe P Hagan GA Rook, Trends Microbiol 2002 10 10 Suppl 38 46 10.1016/S0966-842X(02)02437-X 12377567
47. Immunity to liver stages. P Druilhe L Rénia D Fidock, Malaria: Parasite biology, pathogenesis and protection Washington DC.: AMS Press, Sherman I, 1998 513 543
48. Malaria vaccines: are we getting closer? JE Epstein B Giersing G Mullen V Moorthy TL Richie, Curr Opin Mol Ther 2007 9 12 24 17330398 (Pubitemid 46438445)
49. Prime-boost vectored malaria vaccines: progress and prospects. AV Hill A Reyes-Sandoval G O'Hara K Ewer A Lawrie A Goodman A Nicosia A Folgori S Colloca R Cortese SC Gilbert SJ Draper, Hum Vaccin 2010 6 78 83 10.4161/hv.6.1.10116 20061802
50. Immunological mechanisms underlying protection mediated by RTS, S: a review of the available data. V Moorthy WR Ballou, Malar J 2009 8 312 10.1186/1475-2875-8-312 20042088
51. Cellular effector mechanisms against Plasmodium liver stages. U Frevert E Nardin, Cell Microbiol 2008 10 1956 1967 10.1111/j.1462-5822.2008.01211.x 18647171
52. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. P Daubersies AW Thomas P Millet K Brahimi JA Langermans B Ollomo L BenMohamed B Slierendregt W Eling A Van Belkum G Dubreuil JF Meis C Guerin-Marchand S Cayphas J Cohen H Gras-Masse P Druilhe LB Mohamed, Nat Med 2000 6 1258 1263 10.1038/81366 11062538
53. Immunogenicity and protective efficacy of Plasmodium falciparum liver-stage Ag-3 in Aotus lemurinus griseimembra monkeys. BL Perlaza C Zapata AZ Valencia S Hurtado G Quintero JP Sauzet K Brahimi C Blanc M Arevalo-Herrera P Druilhe S Herrera, Eur J Immunol 2003 33 1321 1327 10.1002/eji.200323339 12731057 (Pubitemid 36609149)
54. Protection against Plasmodium falciparum challenge induced in Aotus monkeys by liver-stage antigen-3-derived long synthetic peptides. BL Perlaza AZ Valencia C Zapata A Castellanos JP Sauzet C Blanc J Cohen M Arevalo-Herrera G Corradin S Herrera P Druilhe, Eur J Immunol 2008 38 2610 2615 10.1002/eji.200738055 18792413
55. Lipopeptide immunization without adjuvant induces potent and long- lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. L BenMohamed H Gras-Masse A Tartar P Daubersies K Brahimi M Bossus A Thomas P Druilhe, Eur J Immunol 1997 27 1242 1253 10.1002/eji.1830270528 9174617 (Pubitemid 27197230)
56. Genetic immunisation by liver stage antigen 3 protects chimpanzees against malaria despite low immune responses. P Daubersies B Ollomo JP Sauzet K Brahimi BL Perlaza W Eling H Moukana P Rouquet C de Taisne P Druilhe, PLoS ONE 2008 3 2659 10.1371/journal.pone.0002659 18628827
57. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. L BenMohamed A Thomas P Druilhe, Infect Immun 2004 72 4376 4384 10.1128/IAI.72.8.4376-4384.2004 15271893 (Pubitemid 38989293)
58. Interferon-{gamma} - central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria. MB McCall RW Sauerwein, J Leukoc Biol 2010 88 1131 1143 10.1189/jlb.0310137 20610802
59. Protection against a malaria challenge by sporozoite inoculation. M Roestenberg M McCall J Hopman J Wiersma AJ Luty GJ van Gemert M van de Vegte-Bolmer B van Schaijk K Teelen T Arens L Spaarman Q de Mast W Roeffen G Snounou L Renia A van der Ven CC Hermsen R Sauerwein, N Engl J Med 2009 361 468 477 10.1056/NEJMoa0805832 19641203
60. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. SM Keating P Bejon T Berthoud JM Vuola S Todryk DP Webster SJ Dunachie VS Moorthy SJ McConkey SC Gilbert AV Hill, J Immunol 2005 175 5675 5680 16237057 (Pubitemid 41508049)
61. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. DP Webster S Dunachie JM Vuola T Berthoud S Keating SM Laidlaw SJ McConkey I Poulton L Andrews RF Andersen P Bejon G Butcher R Sinden MA Skinner SC Gilbert AV Hill, Proc Natl Acad Sci USA 2005 102 4836 4841 10.1073/pnas.0406381102 15781866 (Pubitemid 40471540)
62. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. WH Reece M Pinder PK Gothard P Milligan K Bojang T Doherty M Plebanski P Akinwunmi S Everaere KR Watkins G Voss N Tornieporth A Alloueche BM Greenwood KE Kester KP McAdam J Cohen AV Hill, Nat Med 2004 10 406 410 10.1038/nm1009 15034567 (Pubitemid 38508520)
63. The interferon compartment of the immune response in human malaria: II. Presence of serum-interferon gamma following the acute attack. A Rhodes-Feuillette M Bellosguardo P Druilhe JJ Ballet S Chousterman M Canivet J Peries, J Interferon Res 1985 5 1 169 178 3921628 (Pubitemid 15086881)
64. Protective value of elevated levels of gamma interferon in serum against exoerythrocytic stages of Plasmodium falciparum. P Deloron C Chougnet JP Lepers S Tallet P Coulanges, J Clin Microbiol 1991 29 9 1757 1760 1774292
65. Plasmodium falciparum liver-stage antigen-1 peptide-specific interferon-gamma responses are not suppressed during uncomplicated malaria in African children. AJ Luty M Bongartz P Rezbach JF Faucher MR Hollingdale PG Kremsner, Eur Cytokine Netw 2001 12 647 653 11781192 (Pubitemid 34062152)
66. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. AV Hill J Elvin AC Willis M Aidoo CE Allsopp FM Gotch XM Gao M Takiguchi BM Greenwood AR Townsend AJ McMichael HC Whittle, Nature 1992 360 434 439 10.1038/360434a0 1280333
67. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3. M Aidoo A Lalvani SC Gilbert JT Hu P Daubersies N Hurt HC Whittle P Druihle AV Hill, Infect Immun 2000 68 227 232 10.1128/IAI.68.1.227-232.2000 10603392 (Pubitemid 30016701)
68. HLA class I-associated resistance to severe malaria: a parasitological re-assessment. A Dieye C Rogier JF Trape JL Sarthou P Druilhe, Parasitol Today 1997 13 48 49 10.1016/S0169-4758(96)20062-6 15275122 (Pubitemid 27080897)
69. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. SL Hoffman LM Goh TC Luke I Schneider TP Le DL Doolan J Sacci P de la Vega M Dowler C Paul DM Gordon JA Stoute LW Church M Sedegah DG Heppner WR Ballou TL Richie, J Infect Dis 2002 185 1155 1164 10.1086/339409 11930326 (Pubitemid 34297774)
70. Clinical malaria vaccine development. RW Sauerwein, Immunol Lett 2009 122 115 117 10.1016/j.imlet.2008.11.008 19100773
71. Activity of human volunteer sera to candidate Plasmodium falciparum circumsporozoite protein vaccines in the inhibition of sporozoite invasion assay of human hepatoma cells and hepatocytes. MR Hollingdale A Appiah P Leland VE do Rosario D Mazier S Pied DA Herrington JD Chulay WR Ballou T Derks SH Yap RL Beaudoin JP Verhave, Trans R Soc Trop Med Hyg 1990 84 325 329 10.1016/0035-9203(90)90303-V 2175464 (Pubitemid 20204300)
72. Effect of antibodies to recombinant and synthetic peptides on Plasmodium falciparum sporozoites in vitro. D Mazier S Mellouk RL Beaudoin B Texier P Druilhe W Hockmeyer P Trosper Y Paul Y Charoenvit J Young F Miltgen L Chedid JP Chigot B Galley O Brandicourt M Gentilini, Science 1986 231 156 159 10.1126/science.3510455 3510455 (Pubitemid 16154706)
73. Plasmodium falciparum sporozoite invasion is inhibited by naturally acquired or experimentally induced polyclonal antibodies to the STARP antigen. V Pasquetto DA Fidock H Gras E Badell W Eling WR Ballou J Belghiti A Tartar P Druilhe, Eur J Immunol 1997 27 2502 2513 10.1002/eji.1830271007 9368603 (Pubitemid 27453837)
74. Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo. K Brahimi E Badell JP Sauzet L BenMohamed P Daubersies C Guerin-Marchand G Snounou P Druilhe, Infect Immun 2001 69 3845 3852 10.1128/IAI.69.6.3845-3952.2001 11349050 (Pubitemid 32493304)
75. Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum in parasite-host cell interactions. HM Muller E Scarselli A Crisanti, Parassitologia 1993 35 Suppl 69 72 8233617
76. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. O Silvie JF Franetich S Charrin MS Mueller A Siau M Bodescot E Rubinstein L Hannoun Y Charoenvit CH Kocken AW Thomas GJ Van Gemert RW Sauerwein MJ Blackman RF Anders G Pluschke D Mazier, J Biol Chem 2004 279 9490 9496 10.1074/jbc.M311331200 14676185 (Pubitemid 38296016)
77. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. P Potocnjak N Yoshida RS Nussenzweig V Nussenzweig, J Exp Med 1980 151 1504 1513 10.1084/jem.151.6.1504 6991628 (Pubitemid 10062946)
78. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. N Yoshida RS Nussenzweig P Potocnjak V Nussenzweig M Aikawa, Science 1980 207 71 73 10.1126/science.6985745 6985745 (Pubitemid 10142301)
79. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. DL Doolan M Sedegah RC Hedstrom P Hobart Y Charoenvit SL Hoffman, J Exp Med 1996 183 1739 1746 10.1084/jem.183.4.1739 8666931
80. IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. S Mellouk SJ Green CA Nacy SL Hoffman, J Immunol 1991 146 3971 3976 1903415